In patients with non-small cell lung cancer (NSCLC) ineligible for standard chemotherapy, a first-line checkpoint inhibitor nearly doubled overall survival (OS) at two years regardless of underlying histology, performance status or programmed death ligand-1 (PD-L1) expression.
It is the first randomized study in NSCLC patients with poor prognosis and no EGFR or ALK mutations to show an OS for a first-line checkpoint inhibitor regardless of histology, reported Siow Ming Lee, MD, PhD,